Can glucagon-like peptide-1 receptor agonists cause depression?

GLP-1 Receptor Agonists and Depression Risk

The evidence on GLP-1 receptor agonists causing depression is contradictory and mixed, but the highest quality recent meta-analysis of randomized controlled trials shows no increased risk of psychiatric adverse events or worsening depressive symptoms compared to placebo 1.

Key Evidence Analysis

Strongest Evidence: Meta-Analysis of RCTs (2025)

The most robust evidence comes from a 2025 systematic review and meta-analysis of 80 randomized placebo-controlled trials involving 107,860 patients 1. This study found:

• No significant difference in serious psychiatric adverse events (log[RR] = -0.02; 95% CI, -0.20 to 0.17)
• No significant difference in nonserious psychiatric adverse events (log[RR] = -0.03; 95% CI, -0.21 to 0.16)
• No change in depressive symptom severity (g = 0.02; 95% CI, -0.51 to 0.55)
• Improvements in quality of life measures across mental health, physical health, and weight-related domains

This provides strong reassurance regarding psychiatric safety.

Contradictory Observational Data

However, real-world observational studies show conflicting results:

Studies suggesting increased risk:

• A 2026 cohort study found a 9% relative increase in depression risk (HR 1.09) with GLP-1 RAs versus SGLT2 inhibitors, translating to a 2.2% absolute risk difference over 1 year 2
• Another 2024 study reported a 195% higher risk of major depression in obesity patients on GLP-1 RAs 3

Studies showing neutral or protective effects:

• A 2025 Medicare study found no increased risk versus SGLT2 inhibitors (HR 1.07, CI 0.98-1.18) and actually showed 10% lower risk versus DPP-4 inhibitors (HR 0.90) 4
• A 2024 Veterans Health Administration study found no significant increase (RR 1.02, CI 0.97-1.07) 5

Clinical Interpretation

Why the Discrepancy?

The observational studies suffer from:

• Selection bias: Patients prescribed GLP-1 RAs may have baseline characteristics predisposing to depression (obesity itself is associated with depression)
• Outcome misclassification: Depression diagnoses in administrative databases may not capture true clinical depression
• Confounding by indication: Weight loss itself can trigger mood changes in susceptible individuals
• Heterogeneous populations: Different baseline psychiatric status across studies

The Balanced Recommendation

For patients without prior mood disorders: The preponderance of high-quality RCT evidence suggests GLP-1 RAs do not cause depression and may improve quality of life. The observational signals are likely confounded.

For patients with prior depression or psychiatric history: Exercise heightened vigilance during the first 6 months of therapy, particularly in adults ≥65 years where the association appears stronger 2. The absolute risk increase, if real, is modest (2.2% over 1 year).

Practical Management Algorithm

1. Pre-prescription screening:

   • Document current mood symptoms
   • Assess history of depression, anxiety, or suicidal ideation
   • Note if patient is ≥65 years (higher risk period)

2. Monitoring schedule:

   • Month 1-6: Most critical period for any potential psychiatric effects
   • Check-in at 1 month, 3 months, and 6 months
   • Ask specifically about mood changes, anhedonia, sleep disturbance, appetite changes beyond expected medication effects

3. Red flags requiring immediate evaluation:

   • New or worsening depressive symptoms
   • Suicidal ideation
   • Severe anxiety or panic attacks
   • Significant behavioral changes

4. Risk-benefit consideration:

   • Do not withhold GLP-1 RAs based solely on depression concerns in patients who would benefit metabolically
   • The mortality benefit is substantial (26% reduction in all-cause mortality) 2
   • Quality of life improvements are consistently demonstrated 1

Critical Caveats

• The FDA warning on suicidal thoughts for weight-loss formulations is based on post-marketing surveillance, not controlled trials
• Most RCTs systematically excluded patients with significant psychiatric comorbidities, limiting generalizability 6
• The association may be stronger in obesity treatment (non-diabetic) populations versus diabetes populations 3
• Individual patient factors (age, baseline psychiatric status, social support) matter more than population-level statistics

The evidence does not support routinely avoiding GLP-1 RAs due to depression concerns, but does support enhanced monitoring in the first 6 months, particularly in older adults and those with psychiatric history.